Physician profile
Saissy E Kendig
NPI 1811418619
$2,123.60
in general payments reported to CMS, 2019-2025
18 companies · $440 in 2025
The $440 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $311 · 2022: $333 · 2023: $308 · 2024: $730 · 2025: $440.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,479.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,478.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $439.54 | 2021-2025 | |
| Lundbeck LLC | $256.76 | 2021-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $206.73 | 2021-2025 | Rexulti, Nuedexta, Abilify Maintena |
| Sunovion Pharmaceuticals INC. | $156.05 | 2021-2022 | |
| Alkermes, INC. | $140.75 | 2023-2025 | Lybalvi, Aristada |
| Axsome Therapeutics, INC. | $127.40 | 2023-2024 | Auvelity |
| Neurocrine Biosciences, INC. | $110.24 | 2021-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $103.13 | 2024-2025 | Hetlioz, Fanapt |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $99.75 | 2023-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $97.64 | 2022-2025 | Trintellix, Vyvanse |
| Corium, LLC | $92.69 | 2024 | Azstarys, Azstarys |
| Supernus Pharmaceuticals, INC. | $70.68 | 2022-2025 | Qelbree, Qelbree |
| E.R. Squibb & Sons, L.L.C. | $59.51 | 2024-2025 | Cobenfy |
| Sage Therapeutics, LLC | $55.93 | 2024-2025 | Zurzuvae |
| Janssen Pharmaceuticals, INC | $53.78 | 2023 | Spravato, Invega Sustenna |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $20.95 | 2024 | |
| Tris Pharma INC | $18.75 | 2024 | Dyanavel Xr |
| Noven Therapeutics, LLC | $13.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saissy Kendig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.